Lyell Immunopharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is a U.S.-listed biopharmaceutical company trading on the Nasdaq in the United States under the ticker LYEL. Headquartered in South San Francisco, California, the company is focused on next-generation cell therapy, with an emphasis on CAR T-cell therapies for hematologic malignancies and, increasingly, selected solid tumors. For French-speaking investors, Lyell is a classic clinical-stage biotechnology story: ambitious platform science, a pipeline still in development, and a high-risk/high-upside profile that depends heavily on clinical execution. Lyell was founded in the 2010s around a central scientific thesis: conventional CAR T cells can be improved by engineering them to resist exhaustion, preserve stem-like qualities, and sustain anti-tumor activity in the hostile tumor microenvironment. The company’s core strategy is to use an integrated set of internal technologies to reprogram CAR T cells so they can generate deeper and more durable responses. Its business model is that of a pre-commercial R&D company, funded primarily through capital markets and targeted licensing or acquisition activity rather than recurring product sales. The company’s lead clinical asset is ronde-cel, or rondecabtagene autoleucel, also associated with the LYL314 program. This is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for aggressive B-cell lymphoma. In 2026, Lyell said it had advanced two pivotal studies around the program, including a randomized Phase 3 head-to-head trial versus established CAR T therapies in second-line large B-cell lymphoma, a meaningful competitive milestone in a crowded hematology market. Lyell is also developing LYL273, a GCC-targeted CAR T candidate for refractory metastatic colorectal cancer, which is in Phase 1 and expands the platform into solid tumors. From a competitive standpoint, Lyell operates in a field dominated by major hematology-oncology players and specialized cell therapy companies. Its differentiation is based on product design, clinical intensity, and manufacturing capability. On that front, the company highlights its LyFE manufacturing center, which is intended to support both late-stage trials and eventual commercial launch. Manufacturing execution matters greatly in CAR T, where scale, consistency, and supply reliability can be as important as clinical data. Recent highlights include continued progress in ronde-cel trials during 2025-2026, favorable clinical data suggesting promising response rates and safety, and the acquisition of LYL273, which broadened the pipeline. Lyell also strengthened its leadership and clinical/commercial organization with new executive appointments, signaling preparation for more advanced regulatory and development milestones. Overall, Lyell Immunopharma is a U.S. Nasdaq biotech with meaningful pipeline optionality, where the investment case will be driven mainly by clinical readouts, regulatory progress, and industrial execution.